Complications of myeloma and its treatments

Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Maki H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.8886-17. [Epub ahead of print]. Severe Hypoglycemia Caused by Lenalidomide. Przybylski DJ et al. Pharmacotherapy. 2017 Nov 20. doi: 10.1002/phar.2061. [Epub ahead of print]. Cardiovascular complications of multiple myeloma in the elderly. Mathur P et al. Expert Rev Cardiovasc Ther. 2017 Nov…

Details

Biology and genetics

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Botta C et al. Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.336. [Epub ahead of print]. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. Gullà A et al.Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.334. [Epub ahead of print]. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences…

Details

Myeloma UK study of patient preferences published

Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…

Details

Supportive treatments

Advances in the Treatment of Paraproteinemic Neuropathy. Nobile-Orazio E et al. Curr Treat Options Neurol. 2017 Oct 16;19(12):43. doi: 10.1007/s11940-017-0479-9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363. doi: 10.1159/000481461. [Epub ahead of print]. Interbody distraction and vertebral body reconstruction with polymethylmethacrylate for the treatment of pathological…

Details